SecBot SecBot
S-3ASR ·Filed Nov 13, 2026

INBX

Inhibrx Biosciences, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed3d 10h ago SEC0002007919-26-000061
Notable filing: S-3ASR
Actionable Insight ▼ Bearish

The ATM provides a flexible capital source but signals that Inhibrx's $199.5M cash balance is insufficient to fund operations through potential ozekibart approval and launch given the $275M debt burden and $38.7M quarterly burn. Monitor the pace of ATM sales and any updates on BLA review timeline for ozekibart, as positive regulatory news could reduce the need for dilutive sales.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

INBX drug pipeline →

ozekibart

▲ Bullish Named in this S-3ASR
Impact
Phase
Filed/PDUFA (BLA accepted by FDA)
Time to market
PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
Next catalyst
PDUFA date · Apr 14, 2027 148d

What to watchThe next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Inhibrx filed an automatic shelf registration (S-3ASR) and a prospectus supplement for an at-the-market (ATM) equity offering of up to $150M in common stock, with Stifel and LifeSci Capital as sales agents. The filing coincides with the same-day release of Q3 2026 results showing a net loss of $38.7M, cash of $199.5M, and $275M in outstanding debt, indicating the company needs capital to fund clinical development and potential commercialization of ozekibart ahead of a BLA filing.

Key Facts

  • S-3ASR filed November 13, 2026 for up to $150M in common stock via ATM offering
  • Sales agents: Stifel, Nicolaus & Company and LifeSci Capital; commission up to 3.0%
  • Q3 2026 net loss of $38.7M ($2.46/share) vs $35.3M ($2.28/share) in Q3 2025
  • Cash and cash equivalents of $199.5M as of September 30, 2026
  • Outstanding loan balance of $275.0M as of Q3 2026 (up from $100.0M in Q3 2025)
  • 14,769,076 shares outstanding as of November 6, 2026; pro forma shares would be ~16.5M if all $150M sold at $87.745
  • Net tangible book deficit of $(85.9)M ($(5.82)/share) as of September 30, 2026
  • BLA for ozekibart in conventional chondrosarcoma accepted by FDA in June 2026

Financial Impact

Up to $150M in gross proceeds from ATM offering; net tangible book value would improve from $(85.9)M to $58.6M if fully sold at $87.745/share, but existing shareholders face ~$84.185/share dilution to new investors

dilutioncashdebtshare count

Risk Factors

  • Immediate and substantial dilution to existing shareholders (estimated $84.185/share dilution at assumed price)
  • Company has $275M in debt and is pre-revenue; cash burn of ~$38.7M/quarter suggests runway of ~5 quarters without ATM proceeds
  • No guarantee of selling any shares under the ATM; market conditions may limit access to capital
  • Short interest of ~23% of shares outstanding as of October 30, 2026 adds downward pressure

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
S-3ASR Filing (Primary)0002007919-26-000061
Exhibit: exhibit45-formofindentures.htm0002007919-26-000061
Exhibit: exhibit49-formofpreferreds.htm0002007919-26-000061

Track record

22 reports on INBX

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +29.54% at T+60 after the Jun 11, 2026 report. 6 of 12 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $80.43 Now $77.66 −3.44% settles Feb 12
  2. Nov 13, 20263d ago S-3ASR Bearish 5/10 Viewing Entry $82.85 Now $77.66 +6.26% settles Feb 12
  3. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $83.30 Now $77.66 −6.77% settles Feb 12
  4. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $73.29 Now $77.66 +5.96% settles Jan 26
  5. Oct 14, 20264w ago Insider Buy Bullish 4/10 Entry $90.50 Now $77.66 −14.19% settles Jan 12
  6. Sep 28, 20267w ago Insider Cluster Bullish 5/10 Entry $104.83 Now $77.66 −25.92% settles Dec 23
  7. Sep 17, 20268w ago Insider Cluster Bullish 5/10 Entry $109.35 Now $77.66 −28.98% settles Dec 14
  8. Sep 15, 20268w ago Insider Cluster Neutral 4/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
  9. Sep 15, 20268w ago 144 Neutral 2/10 Entry $101.77 Now $77.66 −23.69% settles Dec 10
  10. Sep 14, 20269w ago 144 Neutral 2/10 Entry $105.61 Now $77.66 −26.47% settles Dec 9
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026